CA
NZ
UK
AU
IND
US
● The company's outlook disappointed, overshadowing the quarterly beat.
● Fortrea raised the midpoint of its full-year revenue guidance to $2.68 billion.
● The company plans a supplementalBiologicsLicense Application for lifileucel in 2027.
● 2026 revenue guidance was raised to $91 billion to $92 billion.
● Lilly raised 2026 revenue guidance to $91 billion to $92 billion.
● Health care was the best-performing S&P 500 sector, leaving MiMedx out of step.
● Winrevair sales nearly doubled from a year earlier.
● Full-year adjusted EPS guidance of $14.80 to $14.90 fell below the $14.95 consensus.
● Shares traded near $174.00 after being indicated near $192.38 before the open.
● The company authorized a new $1.0 billion share buyback.
Please wait processing your request...